Jane Street Group LLC Has $250,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)

Jane Street Group LLC cut its holdings in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) by 30.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,626 shares of the company’s stock after selling 4,707 shares during the quarter. Jane Street Group LLC’s holdings in ArriVent BioPharma were worth $250,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. FMR LLC lifted its holdings in shares of ArriVent BioPharma by 8.7% during the third quarter. FMR LLC now owns 2,119,695 shares of the company’s stock worth $49,813,000 after buying an additional 169,514 shares during the last quarter. Suvretta Capital Management LLC lifted its holdings in shares of ArriVent BioPharma by 7.7% during the third quarter. Suvretta Capital Management LLC now owns 1,845,162 shares of the company’s stock worth $43,361,000 after buying an additional 132,459 shares during the last quarter. Novo Holdings A S lifted its holdings in shares of ArriVent BioPharma by 0.4% during the third quarter. Novo Holdings A S now owns 1,505,315 shares of the company’s stock worth $35,375,000 after buying an additional 5,315 shares during the last quarter. State Street Corp lifted its holdings in shares of ArriVent BioPharma by 210.4% during the third quarter. State Street Corp now owns 476,809 shares of the company’s stock worth $11,205,000 after buying an additional 323,186 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of ArriVent BioPharma by 153.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 202,368 shares of the company’s stock worth $4,756,000 after buying an additional 122,641 shares during the last quarter. 9.48% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of ArriVent BioPharma in a report on Friday, November 15th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, ArriVent BioPharma has an average rating of “Buy” and an average target price of $36.80.

ArriVent BioPharma Stock Performance

AVBP opened at $24.88 on Friday. ArriVent BioPharma, Inc. has a 1 year low of $14.35 and a 1 year high of $36.37. The stock’s 50 day simple moving average is $28.34 and its 200-day simple moving average is $25.57.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.